1. Home
  2. IRD vs RGS Comparison

IRD vs RGS Comparison

Compare IRD & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • RGS
  • Stock Information
  • Founded
  • IRD 2018
  • RGS 1922
  • Country
  • IRD United States
  • RGS United States
  • Employees
  • IRD N/A
  • RGS N/A
  • Industry
  • IRD
  • RGS Other Consumer Services
  • Sector
  • IRD
  • RGS Consumer Discretionary
  • Exchange
  • IRD NYSE
  • RGS Nasdaq
  • Market Cap
  • IRD 59.1M
  • RGS 54.2M
  • IPO Year
  • IRD N/A
  • RGS 1991
  • Fundamental
  • Price
  • IRD $1.18
  • RGS $20.32
  • Analyst Decision
  • IRD Strong Buy
  • RGS
  • Analyst Count
  • IRD 3
  • RGS 0
  • Target Price
  • IRD $6.33
  • RGS N/A
  • AVG Volume (30 Days)
  • IRD 295.4K
  • RGS 11.2K
  • Earning Date
  • IRD 08-15-2025
  • RGS 08-27-2025
  • Dividend Yield
  • IRD N/A
  • RGS N/A
  • EPS Growth
  • IRD N/A
  • RGS N/A
  • EPS
  • IRD N/A
  • RGS 41.20
  • Revenue
  • IRD $13,651,000.00
  • RGS $199,112,000.00
  • Revenue This Year
  • IRD $51.41
  • RGS N/A
  • Revenue Next Year
  • IRD $68.84
  • RGS N/A
  • P/E Ratio
  • IRD N/A
  • RGS $0.54
  • Revenue Growth
  • IRD N/A
  • RGS N/A
  • 52 Week Low
  • IRD $0.65
  • RGS $15.00
  • 52 Week High
  • IRD $2.09
  • RGS $35.50
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • RGS 36.80
  • Support Level
  • IRD N/A
  • RGS $20.68
  • Resistance Level
  • IRD N/A
  • RGS $23.61
  • Average True Range (ATR)
  • IRD 0.00
  • RGS 1.10
  • MACD
  • IRD 0.00
  • RGS -0.31
  • Stochastic Oscillator
  • IRD 0.00
  • RGS 6.51

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About RGS Regis Corporation

Regis Corp owns, franchises, and operates beauty salons throughout North America and the United Kingdom. The company's locations provide salon products and services to the mass market, including haircutting, styling, and hair coloring. The vast majority of Regis' salons are in strip malls, shopping centers, and Wal-Mart stores in North America and serve price-conscious customers. The company derives the majority of its revenue from these locations. The sale of products also contributes a relatively significant percentage of total sales. Regis also operates a smaller portfolio of premium salons across North America and the U.K. The company's majority brands include SmartStyle, Cost Cutters, and Supercuts.

Share on Social Networks: